周五，H.C. Wainwright分析师维持对Regulus Therapeutics（NASDAQ:RGLS）的买入评级，目标价保持在10.00美元不变，显著高于当前1.38美元的交易价格。根据 InvestingPro ...

As at December 2024, Regulus Therapeutics had cash of US$76m and no debt. Looking at the last year, the company burnt through US$42m. That means it had a cash runway of around 22 months as of December ...

Regulus Therapeutics Inc ( ($RGLS) ) has released its Q4 earnings. Here is a breakdown of the information Regulus Therapeutics Inc presented to ...

Regulus (RGLS) had $75.8M in cash, cash equivalents and short-term investments. The company expects its cash runway to ...

In December 2024, Regulus met with the FDA for an End-of-Phase 1 meeting where they reached alignment on the acceptability of the program's CMC, non-clinical and clinical pharmacology plans and ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Regulus Therapeutics Inc. (RGLS) on Thursday reported a loss of $12.8 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a ...

Regulus Therapeutics Inc.’s RGLS share price has surged by 11.28%, which has investors questioning if this is right time to ...

Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Regulus Therapeutics Inc. (RGLS) on Thursday reported a loss of $12.8 million in its fourth quarter. On a per-share basis, the San Diego-based company said it ...